Free

Beyond Traditional Platforms: CANscript™ - A Better Predictive Model For On...

Event Information

Share this event

Date and Time

Location

Location

MassBio

300 Technology Square

8th Floor

Cambridge, MA 02139

View Map

Event description

Description

Overview:

Delineation of the intra-tumor microenvironment in a dynamic, spatio-temporal setting is critical for investigating the activity and efficacy of candidate oncology drugs. The majority of solid cancers contain unorganized, highly-complex microenvironment wherein a dysregulated phenotypic impacts treatment outcomes at a personalized level.

We have developed and validated a fully human ex-vivo platform technology (CANscript™) using patient material (tumor, autologous ligands and immune cells) to explore the mechanism of and predict efficacy for clinically-directed compounds across several drug classes (Majumder B et al. Nature Comm., 6:6169:1-14 2015).

Drugs that modulate the immune system have been shown to be very effective in some patients. Tumor Infiltrating Lymphocytes (TIL) are required for the function these drugs. In order to understand the role of functional immune phenotypes, we challenged a cohort of patient tumors with a checkpoint inhibitor using CANscript™ data for which will be presented.

This session will explore how CANscript can better enable your translational efforts and aid in advancing your highest potential candidate into successful clinical trials.

Speaker:

Mark Paris, PhD, Associate Director for Translational Applications, Mitra Biotech

Share with friends

Date and Time

Location

MassBio

300 Technology Square

8th Floor

Cambridge, MA 02139

View Map

Save This Event

Event Saved